A5073660687- Inflammatory Bowel Disease
- Microscopic Colitis
- COVID-19 and healthcare impacts
- Global Health Workforce Issues
- Anesthesia and Pain Management
- Eosinophilic Esophagitis
- Pain Management and Opioid Use
- Rheumatoid Arthritis Research and Therapies
- Pregnancy and Medication Impact
- Anesthesia and Sedative Agents
- Telemedicine and Telehealth Implementation
- Biosimilars and Bioanalytical Methods
- Economic and Financial Impacts of Cancer
- Autoimmune and Inflammatory Disorders Research
- Pharmaceutical studies and practices
- Liver Diseases and Immunity
Pfizer (United States)
2023-2025
Rutgers, The State University of New Jersey
2021-2023
College of Coastal Georgia
2022
Abstract Background Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). The long-term safety, tolerability and efficacy etrasimod are being evaluated in ongoing open-label extension (OLE) study.1 We report updated cumulative safety analysis from UC clinical programme with a maximum 4 years exposure. Methods Patients who received completed phase 2 (OASIS; OASIS OLE), 3...
Abstract Background The Ulcerative Colitis (UC) Narrative global survey assessed aspects of living with UC. This analysis aimed to identify health care disparities, social determinants health, and emotional impacts related UC disease management, patient experience, quality life. Methods was conducted by Harris Poll from August 2017 February 2018 among adults Responses 1000 patients in the United States, Canada, Japan, France, Finland were analyzed based on income, employment status,...
Abstract Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. The long-term, Phase 3b/4 RIVETING study (NCT03281304) assessed efficacy and safety tofacitinib dose reduction from 10 mg twice daily (BID) maintenance therapy to 5 BID in patients (pts) stable remission.1 We present a final analysis after ≥30 months treatment. Methods was double-blind, randomised, parallel-group with 42-month (M) duration. Eligible pts had received ≥2...
The coronavirus disease 2019 (COVID-19) pandemic created challenges related to management of patients with ulcerative colitis (UC). UC Narrative COVID-19 survey was conducted from August December 2021 among adults the United States, Canada, Japan, France, and Finland. Patients were questioned on management, health care access experience, preferences for interactions their doctor. Data analyzed descriptively. In total, 584 qualified completed survey. Compared 2019, 25% experienced more flares...
The global coronavirus 2019 (COVID-19) pandemic created many challenges in healthcare provision. This study aimed to evaluate the impact of COVID-19 on people living with rheumatoid arthritis (RA). RA Narrative survey was conducted online among who resided Brazil, Canada, France, Japan, and US from August September 2021. examined disease management, access experiences, participant preferences for interactions their doctor. Overall, 500 participants completed survey: 100 each US. Emotional...
Introduction: The COVID-19 pandemic presented challenges around disease management, lifestyle changes, and provision of care for patients (pts) with ulcerative colitis (UC). Methods: This UC Narrative global survey (United States, Canada, Japan, France, Finland) was conducted by Harris Poll between 25 August 13 December 2021, among 584 pts (confirmed endoscopy) aged ≥ 18 years who had attended a gastroenterologist or internist’s office in the past 3 years, not colectomy, ever taken...
Introduction: The UC Narrative global survey assessed various aspects of living with UC, including gaps in patient (pt) care and communication between pts physicians. This analysis aimed to identify health disparities, social determinants health, emotional impacts related disease management, healthcare experience, overall quality life. Methods: was conducted by Harris Poll (Aug 2017–Feb 2018). included 1,000 diagnosed (confirmed endoscopy) from the United States, Canada, Japan, France,...